Get the tools used by (smart)2 investors.

Amneal Pharmaceuticals Inc Class ANASDAQGS:AMRX

United States / Healthcare / Pharmaceuticals

Join now and get access to the full platform

Exchange Data

Hide this widget
8.36 USD
Price
-0.17 (-1.99%)
Day change
5.18 - 9.47
52-week range

Summary of Amneal Pharmaceuticals Inc Class A

Hide this widget

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars,...

Dec 31, 2024
Latest Report
May 2, 2025
Next Earnings
Filings

Price History

Chart Gallery
Hide this widget
Loading chart...

Data could not be retrieved

Data Explorer

Hide this widget

Peer Benchmarks

Hide this widget
  AMRX Peers Sector
Market Cap
2.591 B3.862 B65.396 M
Price % of 52 Week High
87.0%55.4%62.3%
Dividend Yield
0.0%0.0%0.0%
Shareholder Yield
6.3%19.9%-0.7%
1 Year Price Total Return
36.6%-29.3%-11.0%
Beta (5 Year)
1.051.050.64

Finbox Fair Value

Hide this widget
What is Finbox Fair Value?
A stock's fair value is its real or underlying intrinsic worth.
Read more about Finbox's Fair Value methodology.
USD
Average
Upside
Uncertainty
You need an account to use this feature
Sign Up
Or
Log In

Financial Health

Health Details
Hide this widget
GREAT
Financial Health for Amneal Pharma A is determined by ranking the company on over 100 factors against companies in the Healthcare sector and operating in Developed economic markets.

Financial Models for Amneal Pharmaceuticals Inc Class A

Model Gallery
Hide this widget

Historical Financials

Full Financials
Hide this widget
(presentment in millions)Trailing Twelve MonthsFiscal Quarters
Period EndingDec-22Dec-23Dec-24Dec-23Dec-24
Income Statement
Revenue2,2122,3942,794617731
Operating Income2002713487079
Net Profit(130)(84)(117)(99)(31)
Diluted EPS-0.86-0.48-0.38-0.40-0.10
EBITDA440501585127145
Balance Sheet
Cash & ST Invest.289411294112
Current Assets1,4121,3781,5881,3781,588
Total Assets3,7993,4733,5013,4733,501
Current Liabilities7538471,1308471,130
Total Liabilities3,5903,4113,5463,4113,546
Total Equity20961(45)61(45)
Total Debt2,8452,7512,5932,7512,593
Cash Flow Statement
Cash Flow Operations65346295136118
Cash From Investing(174)(69)(63)(32)(16)
Cash From Financing(107)(213)(212)(101)(61)
Free Cash Flow1629923512496

Analyst Notes

March 27, 2025
Hide this widget
    All rights reserved. Terms Of Use